News

Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating belzutifan for advanced clear cell renal cell carcinoma treatment.

Alexa Simon Meara, MD, discusses the importance of including a rheumatology approach to immunotherapy treatment for cancer.

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel therapies.

Joe Leach, MD, discusses how comprehensive biomarker testing has impacted treatment selection for patients with small cell lung cancer.

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum chemotherapy, supported by promising antitumor activity in the phase 2 TROPiCS-03 study.

Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS.

Data from the phase 1 Acclaim-3 trial of quaratusugene ozeplasmid plus atezolizumab in extensive-stage small cell lung cancer showed no dose-limiting toxicities, with the recommended dose set at 0.12 mg/kg for phase 2.

Lutetium 177 dotatate showed activity and met the PFS end point in patients with surgery- or radiation-refractory grade 2/3 meningioma, per a phase 2 trial presented at ASTRO 2024.

Here are some of the highlights from this year's 2024 ASH Annual Meeting & Exposition.

Paolo Ghia, MD, PhD, provides an overview of the CAPTIVATE trial, uncovering what investigators sought to evaluate.

The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting its 100% clinical complete response rate in a phase 2 study.

The NCCN has endorsed the Prolaris prostate cancer prognostic test, reinforcing its position as a critical tool in prostate cancer prognostication.

Cosibelimab is now FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not eligible for curative surgery or radiation.

The following list will provide you with suggestions for identifying the go-getters and how to include them in your practice or on your team.

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows promising results in recurrent glioblastoma, and systemic therapy choices impact brain metastases outcomes, according to new research.

Doris K. Hansen, MD, discussed a comprehensive analysis of pretreatment biomarkers associated with outcomes in patients receiving idecabtagene vicleucel therapy

Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 phase studies for patients with multiple myeloma.

A regimen using the PD-L1 inhibitor atezolizumab in the neoadjuvant and adjuvant settings did not improve outcomes in patients with triple-negative breast cancer.

Second-line treatment with lisocabtagene maraleucel in relapsed/refractory LBCL has safety and efficacy outcomes similar to those in the trials supporting its FDA approval.

The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with “good risk” DCIS treated without radiation therapy.

In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS syndrome, with or without MDS.

Outpatient lymphodepletion before brexucabtagene autoleucel was safe and showed similar non-relapse mortality compared with inpatient administration in B-ALL and MCL.

Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive or HER2-negative.

Findings from the BOREAS study showed that navtemadlin as a monotherapy led to safety and efficacy in patients with myelofibrosis who were relapsed or refractory to JAK inhibitors.